Payment overview · 2025
General Payments
$513.51
29 reported records · 11 companies
Healthcare provider profile · identity verified
Audrey K Tolbert, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COOKEVILLE, TN · NPI 1346240009
Verified facts
What the public records show
CMS Open Payments records show Audrey K Tolbert, M.D. received $513.51 in general payments during 2025 across 29 reported records.
Lilly USA, LLC accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.17 | 23.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.54 | 12.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.40 | 11.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.94 | 10.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.94 | 10.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.74 | 8.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $35.69 | 7.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.40 | 5.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.75 | 4.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.14 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.80 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.51 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $120.17 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.88 | 6 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $62.54 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.94 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.74 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.58 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.40 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 91 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
40 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
46 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 874 | 237 |
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 226 |
| Omeprazole | Omeprazole | 606 | 174 |
| Lisinopril | Lisinopril | 453 | 124 |
| Gabapentin | Gabapentin | 437 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 111 |
| Losartan Potassium | Losartan Potassium | 371 | 106 |
| Alprazolam | Alprazolam | 366 | 77 |
| Metformin Hcl | Metformin Hcl | 360 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 110 |
| Simvastatin | Simvastatin | 314 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 77 |
| Prednisone | Prednisone | 264 | 181 |
| Azithromycin | Azithromycin | 248 | 194 |
| Metformin Hcl Er | Metformin Hcl | 248 | 76 |
| Trazodone Hcl | Trazodone Hcl | 242 | 68 |
| Meloxicam | Meloxicam | 207 | 88 |
| Furosemide | Furosemide | 206 | 72 |
| Potassium Chloride | Potassium Chloride | 205 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 192 | 53 |
| Atenolol | Atenolol | 186 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 185 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 48 |
| Sertraline Hcl | Sertraline Hcl | 177 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 156 | 44 |
| Lorazepam | Lorazepam | 155 | 19 |
| Lovastatin | Lovastatin | 155 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 151 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 43 |
| Montelukast Sodium | Montelukast Sodium | 146 | 49 |
| Cefuroxime | Cefuroxime Axetil | 142 | 117 |
| Allopurinol | Allopurinol | 141 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 134 | 104 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 39 |
| Fluconazole | Fluconazole | 127 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 44 |
| Clonazepam | Clonazepam | 114 | 16 |
| Alendronate Sodium | Alendronate Sodium | 113 | 35 |
| Ondansetron Odt | Ondansetron | 112 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 111 | 37 |
| Carvedilol | Carvedilol | 109 | 28 |
| Diazepam | Diazepam | 105 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 29 |
| Synthroid | Levothyroxine Sodium | 101 | 26 |
| Baclofen | Baclofen | 100 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 27 |
| Spironolactone | Spironolactone | 94 | 26 |
| Famotidine | Famotidine | 92 | 34 |
| Mounjaro | Tirzepatide | 91 | 14 |
| Cefdinir | Cefdinir | 90 | 84 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 54 |
| Jardiance | Empagliflozin | 89 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 71 |
| Donepezil Hcl | Donepezil Hcl | 86 | 23 |
| Irbesartan | Irbesartan | 81 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 21 |
| Tramadol Hcl | Tramadol Hcl | 79 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 57 |
| Eliquis | Apixaban | 76 | 19 |
| Nifedipine Er | Nifedipine | 76 | 21 |
| Pregabalin | Pregabalin | 69 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 19 |
| Glimepiride | Glimepiride | 65 | 22 |
| Glipizide | Glipizide | 64 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 29 |
| Memantine Hcl | Memantine Hcl | 63 | 13 |
| Ozempic | Semaglutide | 63 | 11 |
| Estradiol | Estradiol | 61 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 18 |
| Aripiprazole | Aripiprazole | 57 | 18 |
| Buspirone Hcl | Buspirone Hcl | 57 | 14 |
| Fenofibrate | Fenofibrate | 54 | 15 |
| Januvia | Sitagliptin Phosphate | 54 | 15 |
| Mirtazapine | Mirtazapine | 54 | 16 |
| Cephalexin | Cephalexin | 50 | 35 |
| Celecoxib | Celecoxib | 49 | 19 |
| Valacyclovir | Valacyclovir Hcl | 48 | 27 |
| Valsartan | Valsartan | 48 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 46 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 40 | 25 |
| Verapamil Er | Verapamil Hcl | 40 | suppressed |
| Nystatin | Nystatin | 37 | 22 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Bupropion Xl | Bupropion Hcl | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 23 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 13 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Repaglinide | Repaglinide | 28 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 26 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Levoxyl | Levothyroxine Sodium | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 20 |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Humira Pen | Adalimumab | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.51 · 29 records | Lilly USA, LLC | AUSTEDO XR, Cologuard Collection Kit, ELIQUIS, FARXIGA, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, SHINGRIX, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error